Related Experiment Video
Updated: Mar 25, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel
Karan J Abraham1, Xiao Zhang1, Ricardo Vidal1
1Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Abstract:
Dysfunction of key miRNA pathways regulating basic cellular processes is a common driver of many cancers. However, the biological roles and/or clinical applications of such pathways in Merkel cell carcinoma (MCC), a rare but lethal cutaneous neuroendocrine (NE) malignancy, have yet to be determined. Previous work has established that miR-375 is highly expressed in MCC tumors, but its biological role in MCC remains unknown. Herein, we show that elevated miR-375 expression is a specific feature of well-differentiated MCC cell lines that express NE markers. In contrast, miR-375 is strikingly down-regulated in highly aggressive, undifferentiated MCC cell lines. Enforced miR-375 expression in these cells induced NE differentiation, and opposed cancer cell viability, migration, invasion, and survival, pointing to tumor-suppressive roles for miR-375. Mechanistically, miR-375-driven phenotypes were caused by the direct post-transcriptional repression of multiple Notch pathway proteins (Notch2 and RBPJ) linked to cancer and regulation of cell fate. Thus, we detail a novel molecular axis linking tumor-suppressive miR-375 and Notch with NE differentiation and cancer cell behavior in MCC. Our findings identify miR-375 as a putative regulator of NE differentiation, provide insight into the cell of origin of MCC, and suggest that miR-375 silencing may promote aggressive cancer cell behavior through Notch disinhibition.
Insights
MicroRNA-375 (miR-375) acts as a tumor suppressor in Merkel cell carcinoma (MCC), promoting neuroendocrine differentiation and inhibiting cancer progression by targeting the Notch pathway.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA (miRNA) pathway dysfunction drives cancer, but roles in Merkel cell carcinoma (MCC) are unclear.
- miR-375 is highly expressed in MCC tumors, yet its function remains unknown.
- MCC is a rare, lethal cutaneous neuroendocrine malignancy.
Purpose of the Study:
- Investigate the biological role and clinical relevance of miR-375 in MCC.
- Determine the molecular mechanisms underlying miR-375's function in MCC.
- Explore miR-375 as a potential therapeutic target in MCC.
Main Methods:
- Analysis of miR-375 expression in MCC cell lines with varying differentiation and aggressiveness.
- Enforced expression of miR-375 in aggressive MCC cells.
- Assessment of cellular phenotypes including differentiation, viability, migration, and invasion.
- Identification of direct miR-375 targets within the Notch pathway (Notch2, RBPJ).
Main Results:
- Elevated miR-375 expression correlates with well-differentiated MCC cells expressing neuroendocrine markers.
- Down-regulation of miR-375 observed in aggressive, undifferentiated MCC cells.
- Enforced miR-375 expression induced neuroendocrine differentiation and suppressed cancer cell viability, migration, invasion, and survival.
- miR-375 directly represses Notch pathway components (Notch2, RBPJ).
Conclusions:
- miR-375 exhibits tumor-suppressive functions in MCC by promoting neuroendocrine differentiation and inhibiting cancer cell aggressiveness.
- The miR-375/Notch pathway axis is a key regulator of cell fate and behavior in MCC.
- miR-375 silencing may drive aggressive MCC phenotypes via Notch pathway activation, suggesting therapeutic potential.
Related Concept Videos
MicroRNAs
MicroRNAs
Mitogens and the Cell Cycle
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

